Combination of HLA-A24, -DQA1*03, and -DR9 contributes to acute-onset and early complete β-cell destruction in type 1 diabetes: Longitudinal study of residual β-cell function

Diabetes

Volumn 55, Issue 6, 2006, Pages 1862-1868

  Nakanishi, Koji ^a,b   Inoko, Hidetoshi ^c  

^a TORANOMON HOSPITAL   (Japan)

^b Okinaka Memorial Institute for Medical Research   (Japan)

^c TOKAI UNIVERSITY   (Japan)

Author keywords

ADA, American Diabetes Association; CPR, C peptide response; LADA, latent autoimmune diabetes of adults; RFLP, restriction fragment length polymorphism

Indexed keywords

HLA A24 ANTIGEN; HLA DQA1 ANTIGEN; HLA DR ANTIGEN; HLA DR9 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HEREDITY; HLA TYPING; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ADULT; AGE OF ONSET; ALLELES; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FEMALE; GENE FREQUENCY; HLA-A ANTIGENS; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; INCIDENCE; INSULIN-SECRETING CELLS; JAPAN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 33748305619     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db05-1049     Document Type: Article

References (40)

1. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 28 (Suppl. 1): S37-S42, 2005
2. Nakanishi K, Kobayashi T, Murase T, Nakatsuji T, Inoko H, Tsuji K, Kosaka K: Association of HLA-A24 with complete β-cell destruction in IDDM. Diabetes 42:1086-1093, 1993
3. The DCCT Research Group: Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual β-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endcrinol Metab 65:30-36, 1987
4. Alberti KGMM, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 15:539-553, 1998
5. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR: Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42:359-362, 1993
6. Kobayashi T, Itoh T, Kosaka K, Sato K, Tsuji K: Time course of islet cell antibodies and β-cell function in non-insulin-dependent stage of type 1 diabetes mellitus. Diabetes 36:510-517, 1987
7. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y, the Osaka IDDM Study Group: A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 342:301-307, 2000
8. Nakanishi K, Kobayashi T, Miyashita H, Ohkubo M, Sugimoto T, Murase T, Kosaka K, Inouye K, Kono M: Relationships among islet cell antibodies, residual β-cell function, and metabolic control in patients with insulindependent diabetes mellitus of long duration: use of a sensitive C-peptide radioimmunoassay. Metabolism 39:925-930, 1990
9. Schölin A, Björklund L, Borg H, Arnqvist H, Björk E, Blohmé G, Bolinder J, Eriksson JW, Gudbjörnsdottir S, Nyström L, Östman J, Karlsson AF, Sundkvist G: Islet antibodies and remaining β-cell function 8 years after diagnosis of diabetes in young adults: a prospective follow-up of the nationwide diabetes incidence study in Sweden. J Internal Med 255:384-391, 2004
10. Reijonen H, Concannon P: Genetics of type 1 diabetes. In Joslin's Diabetes Mellitus. 14th ed. Kahn CR, Weir GC, King GL, Jacobson AM, Moses AM, Smith RJ, Eds. Philadelphia, Lippincott Williams & Wilkins, 2005, p.355-369
11. Rønningen KS, Spurkland A, Tait BD, Drummond B, Lopez-Larrea C, Baranda FS, Menendez-Diaz MJ, Caillat-Zucman S, Beaurain G, Garchon H-J, Ilonen J, Reijonen H, Knip M, Boehm BO, Rosak C, Löliger C, Kühnl P, Ottenhoff T, Contu L, Carcassi C, Savi M, Zanelli P, Neri TM, Hamaguchi K, Kimura A, Dong RP, Chikuba N, Nagataki S, Gorodezky C, Debaz H, Robles C, Coimbra HB, Martinho A, Ruas MA, Sachs JA, Garcia-Pachedo M, Biro A, Nikaein A, Dombrausky L, Gonwa T, Zmijewski C, Monos D, Kamoun M, Layrisse Z, Magli MC, Balducci P, Thorsby E: HLA class II associations in insulin-dependent diabetes mellitus among blacks, Caucasoids, and Japanese. In HLA 1991. Proceedings of the Eleventh International Histocompatibility Workshop and Conference, Yokohoma, Japan, 6-13 November 1991. Tsuji K, Aizawa M, Sasazuki T, Eds. Oxford, U.K. Oxford University Press, 1992, p.713-722
12. Yasunaga S, Kimura A, Hamaguchi K, Rønningen KS, Sasazuki T: Different contribution of HLA-DR and genes in susceptibility and resistance to insulin-dependent diabetes mellitus (IDDM). Tissue Antigens 47:37-48, 1996
13. Nakanishi K, Kobayashi T, Murase T, Naruse T, Nose Y, Inoko H: Human leukocyte antigen-A24 and - DQA1*0301 in Japanese insulin-dependent diabetes mellitus: independent contributions to susceptibility to the disease and additive contributions to acceleration of β-cell destruction. J Clin Endcrinol Metab 84:3721-3725, 1999
14. Fennessy M, Metcalfe K, Hitman GA, Niven M, Biro PA, Tuomilehto J, Tuomilehto-Wolf E, the Childhood Diabetes in Finland (DiMe) Study Group: A gene in the HLA class I region contributes to susceptibility to IDDM in the Finnish population. Diabetologia 37:937-944, 1994
15. Noble JA, Valdes AM, Bugawan TL, Apple RJ, Thomson G, Erlich HA: The HLA class I A locus affects susceptibility to type 1 diabetes. Hum Immunol 63:657-664, 2002
16. Honeyman MC, Harrison LC, Drummond B, Colman PG, Tait BD: Analysis of families at risk for insulin-dependent diabetes mellitus reveals that HLA antigens influence progression to clinical disease. Mol Med 1:576-582, 1995
17. Robles DT, Eisenbarth GS, Wang T, Erlich HA, Bugawan TL, Babu SR, Barriga K, Norris JM, Hoffman M, Klingensmith G, Yu L, Rewers M, the Diabetes Autoimmunity Study in the Young (DAISY): Identification of children with early onset and high incidence of anti-islet autoantibodies. Clin Immunol 102:217-224, 2002
18. Ikegami H, Makino S, Yamato E, Kawaguchi Y, Ueda H, Sakamoto T, Takekawa K, Ogihara T: Identification of a new susceptibility locus for insulin-dependent diabetes mellitus by ancestral haplotype congenic mapping. J Clin Invest 96:1936-1942, 1995
19. Hattori M, Yamato E, Itoh N, Senpuku H, Fujisawa T, Yoshino M, Fukuda M, Matsumoto E, Toyonaga T, Nakagawa I, Petruzzelli M, McMurray A, Weiner H, Sagai T, Moriwaki K, Shiroishi T, Maron R, Lund T: Cutting edge: homologous recombination of the MHC class I K region defines new MHC-linked diabetogenic susceptibility gene(s) in nonobese diabetic mice. J Immunol 163:1721-1724, 1999
20. Schlesselman JJ, Stolley PD: Research strategies. In Case-Control Studies. Schlesselman JJ, Ed. New York, Oxford University Press, 1982, p.7-26
21. Nakanishi K, Kobayashi T, Inoko H, Tsuji K, Murase T, Kosaka K: Residual β-cell function and HLA-A24 in IDDM: markers of glycemic control and subsequent development of diabetic retinopathy. Diabetes 44:1334-1339, 1995
22. Ota M, Seki T, Fukushima H, Tsuji K, Inoko H: HLA-DRB1 genotyping by modified PCR-RFLP method combined with group-specific primers. Tissue Antigens 39:187-202, 1992
23. Ota M, Seki T, Nomura N, Sugimura K, Mizuki N, Fukushima H, Tsuji K, Inoko H: Modified PCR-RFLP method for HLA-DPB1 and -DQA1 genotyping. Tissue Antigens 38; 60-71, 1991
24. Nomura N, Ota M, Tsuji K, Inoko H: HLA-DQB1 genotyping by a modified PCR-RFLP method combined with group-specific primers. Tissue Antigens 38:53-59, 1991
25. Terasaki PI, Bernoco D, Park MS, Ozturk G, Iwai Y: Microdroplet testing for HLA-A, HLA-B, HLA-C, and HLA-D antigens. Am J Clin Pathol 69:103-120, 1978
26. Moribe T, Kaneshige T, Inoko H: Complete HLA-A DNA typing using the PCR-RFLP method combined with allele group- and sequence-specific amplification. Tissue Antigens 50:535-545, 1997
27. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T: Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In HLA 1991: Proceedings of the Eleventh International Histocompatibility Workshop and Conference, Yokohoma, Japan, 6-13 November 1991. Tsuji K, Aizawa M, Sasazuki T, Eds. Oxford, U.K. Oxford University Press, 1992, p.1065-1220
28. Nakanishi K, Kobayashi T, Miyashita H, Okubo M, Sugimoto T, Murase T, Hashimoto M, Fukuchi S, Kosaka K: Exocrine pancreatic ductograms in insulin-dependent diabetes mellitus. Am J Gastroenterol 89:762-766, 1994
29. Kobayashi T, Tamemoto K, Nakanishi K, Kato N, Okubo M, Kajio H, Sugimoto T, Murase T, Kosaka K: Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 16:780-788, 1993
30. Cox DR, Oakes D: Analysis of Survival Data. London, Chapman and Hall, 1984, p.91-111
31. Sugihara S, Sakamaki T, Konda S, Murata A, Wataki K, Kobayashi Y, Minamitani K, Miyamoto S, Sasaki N Niimi H: Association of HLA-DR, DQ genotype with different β-cell functions at IDDM diagnosis in Japanese children. Diabetes 46:1893-1897, 1997
32. Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H: Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes. Diabetologia 48:294-300, 2005
33. Janeway CA, Travers P, Walport M, Schlomchik M: Immunobiology. The Immune System in Health and Disease. 5th ed. New York, Garland Publishing, 2001
34. Raddrizzani L, Sturniolo T, Guenot J, Bono E, Gallazzi F, Nagy ZA, Sinigaglia F, Hammer J: Different modes of peptide interaction enable HLA-DQ and HLA-DR molecules to bind diverse peptide repertoires. J Immunol 159:703-711, 1997
35. Nakanishi K, Komatsu Y, Kogawa N, Matsushita H: Analysis of eluted peptides from type 1 diabetes-susceptible HLA class II molecules identified novel islet protein, heparin/heparan sulfate-interacting protein. Biochem Biophys Res Commun 329:356-361, 2005
36. Graves PM, Norris JM, Pallansch MA, Gerling IC, Rewers M: The role of enteroviral infections in the development of IDDM: limitations of current approaches. Diabetes 46:161-168, 1997
37. Imagawa A, Hanafusa T, Makino H, Miyagawa J-I, Juto P: High titres of IgA antibodies to enterovirus in fulminant type-1 diabetes. Diabetologia 48:290-293, 2005
38. Kobayashi T, Nakanishi K, Sugimoto T, Itoh T, Murase T, Kosaka K, Tsuji K: Maleness as risk factor for slowly progressive IDDM. Diabetes Care 12:7-11, 1989
39. Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Toyoda T, Maruyama T, Makino H: Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 26:2345-2352, 2003
40. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 53:250-264, 2004